Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.An early phase study of Memory Pharmaceuticals' MEM 1003 in Alzheimer's disease patients has demonstrated that the drug was safe and generally well-tolerated at the dose ranges tested.
Subscribe to our email newsletter
There were no obvious trends in clinical laboratory safety tests, vital signs or electrocardiogram parameters following treatment with MEM 1003. Headache was the most commonly reported adverse event overall.
The results indicated that 10 days of exposure to MEM 1003 did not result in a statistically significant increase or decrease in cognition.
“We were pleased to have achieved the main objective of this study, which confirmed our expectations of the safety profile of MEM 1003,” stated Dr David Lowe, chief scientific officer.
MEM 1003 is a neuronal L-type calcium channel modulator that may have applications in Alzheimer’s disease and other diseases associated with cognitive impairment. By blocking L-type calcium channels, MEM 1003 may regulate the flow of calcium and reestablish normal levels of calcium, thereby enhancing cognition and reducing the progression of Alzheimer’s disease.